BioCardia, Inc. — Filing summary
Entity mismatch: The supplied filing is for Tiger X Medical, Inc. (formerly Cardo Medical, Inc.), not BioCardia, Inc. Verify that this is the intended filing before relying on this summary.
Business context and reporting period
The Form 10-Q covers the quarter and six months ended June 30, 2013. Tiger X had discontinued its former orthopedic-device operations and sold related assets; it now principally collects royalties from Arthrex, promotes the acquired products, seeks a partner or buyer for remaining intellectual property, and evaluates other uses for its cash. The financial statements identify the company as a development-stage entity.
Financial performance and position
Amounts below are in thousands of dollars unless otherwise noted.
- Revenue: Q2 revenue was $69, versus $17 in Q2 2012; six-month revenue was $107, versus $28. Revenue was royalty income under an agreement providing 5% of Arthrex net sales of the acquired products.
- Profit and margins: Q2 gross profit was $69, with no cost of revenue; operating income was $6 and net income was $9, compared with a Q2 2012 net loss of $129. For the first half, operating loss was $20 and net loss was $16, compared with losses of $190 and $184, respectively, in the prior-year period. Gross margin was 100% in both periods.
- Expenses and interest: General and administrative expense was $63 in Q2 and $127 for the first half, down from $149 and $218, respectively, a year earlier. Interest income was $3 for Q2 and $4 for the first half. The company reported no debt or interest expense.
- Cash flow: First-half operating cash flow was positive $1, compared with negative $694 in the first half of 2012. The prior-year period included a substantial income-tax payment; the filing cites $556 in MD&A and $553 in the cash-flow statement. There were no investing or financing cash flows in the 2013 period.
- Liquidity and balance sheet: Cash was $13,269 at June 30, 2013, essentially unchanged from $13,268 at December 31, 2012. Total assets were $13,277; total liabilities were $3, comprising accounts payable and accrued expenses. Stockholders’ equity was $13,274. Management said cash was adequate for the next 12 months and beyond.
Changes, outlook, and risks
- Arthrex royalty revenue rose substantially year over year; management attributed the increase to higher sales of the acquired product line. The company expects royalties to remain its primary revenue source.
- Management attributed lower G&A expense versus 2012 to higher prior-year insurance costs and professional services related to tax issues. It expected G&A to remain at the 2013 level; no quantified revenue or earnings guidance was provided.
- The filing reports disclosure controls and procedures were not effective at June 30, 2013, citing the former CFO’s departure, elimination of the internal accounting and finance department, and insufficient segregation of duties. No material control changes during the quarter were reported.
- Cash balances exceeded FDIC-insured limits by approximately $12.96 million, creating bank-deposit concentration risk. The company also cautioned that forward-looking statements are subject to risks and uncertainties and that interim results may not indicate full-year results.
- The filing reports no material pending legal proceedings and no defaults upon senior securities.
Important facts for investors to verify
- Confirm the issuer and filing: this document names Tiger X Medical, Inc., whereas the request identifies BioCardia, Inc.
- Reconcile the reported first-half 2012 income-tax payment, shown as $556 in MD&A and $553 in the cash-flow statement.
- Review the Arthrex royalty agreement, royalty calculations, and sustainability of product sales that drive the company’s principal revenue.
- Assess the ineffective disclosure controls, limited finance staffing, and management’s plans to address control deficiencies.
- Evaluate the concentration of cash above FDIC-insured limits and the basis for management’s liquidity outlook.